Literature DB >> 21594997

An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses.

Angela E Lin1, Kathryn E Singh, Arthur Strauss, Son Nguyen, Kristyn Rawson, Virginia E Kimonis.   

Abstract

We describe an infant male of Cambodian background who has typical craniofacial features of mycophenolate mofetil (MMF) embryopathy and a complex congenital heart defect (CHD) (double outlet right ventricle, mitral atresia, pulmonic stenosis, and total anomalous pulmonary venous return). Together with four case reports and the 20 patients included in two recent reviews, we report 24 (19 affected, five normal) patients with this pattern of anomalies. Eight (33%) have a CHD, most commonly, conotruncal or aortic arch defects (6/8, 75%). This would support the hypothesis that disturbance of cranial neural crest migration occurs in exposed infants, and may predict which additional anomalies will be observed in the future. We also attempted to score the severity of the facial anomalies in each MMF patient using a system created by plastic surgeons for patients with hemifacial microsomia. This classification had modest utility in comparing severity and correlating facial to extracranial defects. The findings are viewed with caution because of the preliminary methodology. Finally, since several exposed infants have been reported to be minimally affected, we remind clinicians to be sensitive to the potential mild expression of the effects of this teratogen. This awareness may influence clinical management of apparently normal MMF-exposed individuals.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594997     DOI: 10.1002/ajmg.a.33934

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  12 in total

Review 1.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

2.  What Is the Teratogenic Risk of Mycophenolate?

Authors:  Ranjit I Kylat
Journal:  J Pediatr Genet       Date:  2017-01-02

Review 3.  Genetic basis of congenital cardiovascular malformations.

Authors:  Seema R Lalani; John W Belmont
Journal:  Eur J Med Genet       Date:  2014-04-30       Impact factor: 2.708

4.  [Systemic drug treatment during pregnancy].

Authors:  Maximilian Riedel; Bettina Kuschel
Journal:  Hautarzt       Date:  2020-04       Impact factor: 0.751

Review 5.  Paediatric use of mycophenolate mofetil.

Authors:  Heather J Downing; Munir Pirmohamed; Michael W Beresford; Rosalind L Smyth
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

6.  Hirschsprung-like disease is exacerbated by reduced de novo GMP synthesis.

Authors:  Jonathan I Lake; Olga A Tusheva; Brittany L Graham; Robert O Heuckeroth
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  Myasthenia gravis during pregnancy.

Authors:  Shahnaz Akhtar Chaudhry; Biruthvie Vignarajah; Gideon Koren
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

Review 8.  Update on the Teratogenicity of Maternal Mycophenolate Mofetil.

Authors:  Lisa A Coscia; Dawn P Armenti; Ryan W King; Nicole M Sifontis; Serban Constantinescu; Michael J Moritz
Journal:  J Pediatr Genet       Date:  2015-06

9.  Neural crest requires Impdh2 for development of the enteric nervous system, great vessels, and craniofacial skeleton.

Authors:  Jonathan I Lake; Marina Avetisyan; Albert G Zimmermann; Robert O Heuckeroth
Journal:  Dev Biol       Date:  2015-11-10       Impact factor: 3.582

10.  ACG Clinical Guideline: Liver Disease and Pregnancy.

Authors:  Tram T Tran; Joseph Ahn; Nancy S Reau
Journal:  Am J Gastroenterol       Date:  2016-02-02       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.